Mobile

This is a short study, performed in different countries, to investigate how well one dose of mirabegron mirabegron suspension is taken, how long it stays in the body and how well it is tolerated in ch...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-000700-26

This is a short study, performed in different countries, to investigate how well one dose of mirabegron mirabegron suspension is taken, how long it stays in the body and how well it is tolerated in children aged 5 to less than 12 years with symptoms of overactive bladder (possibly caused by nerve dysfunction)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the trial is to evaluate the pharmacokinetics (PK) of mirabegron oral suspension after single dose administration in children with neurogenic detrusor overactivity (NDO) or overactive bladder (OAB).

Critère d'inclusion

  • -neurogenic detrusor overactivity (NDO) -overactive bladder (OAB)

Liens